DrugPatentWatch Database Preview
MELOXICAM - Generic Drug Details
» See Plans and Pricing
What are the generic drug sources for meloxicam and what is the scope of patent protection?
Meloxicam
is the generic ingredient in five branded drugs marketed by Lupin Ltd, Zyla, Baudax, Avondale Pharms, Tersera, Anda Repository, Apotex Inc, Aurobindo Pharma, Cipla, Cr Double Crane, Dr Reddys Labs Inc, Glenmark Generics, Heritage Pharma, Impax Labs Inc, Lupin Pharms, Mylan, Nostrum Labs Inc, Puracap Pharm, Roxane, Strides Pharma, Sun Pharm Inds Inc, Taro, Unichem, Yabao Pharm, Yung Shin Pharm, Zydus Pharms Usa, and Boehringer Ingelheim, and is included in twenty-eight NDAs. There are nine patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.Meloxicam has fifty-one patent family members in twenty-three countries.
There are twenty-two drug master file entries for meloxicam. Thirty-four suppliers are listed for this compound. There is one tentative approval for this compound.
Summary for MELOXICAM
| International Patents: | 51 |
| US Patents: | 9 |
| Tradenames: | 5 |
| Applicants: | 27 |
| NDAs: | 28 |
| Drug Master File Entries: | 22 |
| Suppliers / Packagers: | 34 |
| Bulk Api Vendors: | 126 |
| Clinical Trials: | 79 |
| Patent Applications: | 36 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price trends for MELOXICAM |
| Drug Sales Revenues: | Drug sales revenues for MELOXICAM |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for MELOXICAM |
| DailyMed Link: | MELOXICAM at DailyMed |
Recent Clinical Trials for MELOXICAM
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Daewoong Pharmaceutical Co. LTD. | Phase 1 |
| Beijing Tongren Hospital | Phase 1 |
| Axsome Therapeutics, Inc. | Phase 3 |
Generic filers with tentative approvals for MELOXICAM
| Applicant | Application No. | Strength | Dosage Form |
| Start Trial | Start Trial | 10MG | CAPSULE;ORAL |
| Start Trial | Start Trial | 5MG | CAPSULE;ORAL |
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Pharmacology for MELOXICAM
| Drug Class | Nonsteroidal Anti-inflammatory Drug |
| Mechanism of Action | Cyclooxygenase Inhibitors |
US Patents and Regulatory Information for MELOXICAM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Heritage Pharma | MELOXICAM | meloxicam | TABLET;ORAL | 077936-001 | Jul 19, 2006 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| Cipla | MELOXICAM | meloxicam | TABLET;ORAL | 077929-002 | Jul 19, 2006 | AB | RX | No | No | Start Trial | Start Trial | Start Trial | |||
| Mylan | MELOXICAM | meloxicam | TABLET;ORAL | 077934-002 | Jul 20, 2006 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MELOXICAM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Avondale Pharms | MOBIC | meloxicam | SUSPENSION;ORAL | 021530-001 | Jun 1, 2004 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for MELOXICAM
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2017517551 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2010138539 | Start Trial |
| Philippines | 12016502336 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2021 - 2022
NCE-1 Patent Challenge Dates 2021 - 2022
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2021, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
